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We performedMBL2 genotyping in 47 CF patients—cared of at the regional CF Centre of Trieste—trying to establish a correlation within
allelic variants of MBL2 and modification of patients’ clinical outcome. FEV1 values were significantly lowered and a significantly earlier
age at onset of Pseudomonas aeruginosa colonisation was found in CF patients with at least one MBL2 variant.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Mannose-binding lectin; MBL2; Cystic fibrosis; Modifier genes; Respiratory infections1. Introduction
The importance of the MBL2 gene as a modifier locus in
the phenotype of CF patients has been demonstrated by
several authors [1–3]. Mannose-binding lectin (MBL) is a
serum protein that plays a pivotal role in natural immune
response. MBL acts as an ‘‘ante-antibody’’ and can enhance
opsonisation, or can activate the classical pathway of the
complement on certain bacteria, viruses and fungi [4,5].
Three dominant missense mutations—at codon 52, 54 and
57—were described in the first exon of the MBL2 gene,
which encodes MBL and are proved responsible for reduced
levels of the protein in serum [6].
In this study, we investigated whether MBL2 variants
could modify the clinical outcome of selected CF patients
admitted to the Cystic Fibrosis Regional Centre of Trieste
(Friuli Venezia Giulia, Italy) with the aim of providing new1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
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lung diseases in CF patients.2. Methods
2.1. Patients
We examined 47 patients admitted to the Regional CF
Centre of Trieste (Italy), whose diagnosis was made after
two positive sweat tests performed according to Gibson and
Cooke [7]. Patients have been regularly followed-up since
1990.
Since all patients were able to secrete sputum, Pseudo-
monas aeruginosa (PA) and Burkholderia cepacia (BC)
colonisations were defined as the presence of PA or BC in
the sputum culture at least in three consecutive samples
collected in a 6-month period.
Pulmonary function was evaluated on the basis of forced
expiratory volume in 1 s (FEV1) expressed as a percentage
of expected values corrected for sex and height [8]. For
every patient, the best value of all records collected during
each calendar year was taken into consideration. FEV14 (2005) 189 – 191ed by Elsevier B.V. All rights reserved.
Table 1
Clinical characteristics of the 47 CF patients
Patients M F Total
Number 25 22 47
Median age at diagnosis (years) 2.76 0.68
Present median age (years) 19.90 16.95
PA colonization 20 19 39
Median age of PA colonization (years) 10.23 7.04
BC colonization 4 1 5
Mean FEV1 88% 83%
Severe/severe CFTR genotype 14 14 28
Mild/unknown CFTR genotype 11 8 19
Table 3
General and clinical characteristics of CF patients divided into normal MBL
producers (A/A) and lower MBL producers (A/0 and 0 /0)
CF patients MBL2 genotypes
A/0 and
0 /0
A/A p
N 23 24
Gender (M/F) 13 /10 12 /12 ns
Median age at diagnosis (years) 1.48 1.66 ns
Actual median age (years) 17.3 19.9 ns
Mean follow-up duration (years) 15.1 17.9 ns
PA colonization 20 19 ns
Median age of PA colonization (years) 6.29 11.24 0.037T
BC colonization 3 2 ns
Severe/severe CFTR genotype 14 14 ns
Mild/unknown CFTR genotype 9 10 ns
Mean FEV1 values 71.3% 94% 0.04T
Mean FEV1 in non-PA colonized 85% 92% ns
Mean FEV1 in PA colonized 70% 90.2% 0.04T
Mean FEV1 in severe/severe CF phenotypes 74.6% 90.2% 0.01T
Mean FEV1 in mild/unknown CF
phenotypes
66% 82.7% ns
* p =20 (p =B2 0.5).
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a bronchodilator.
2.2. CFTR and MBL2 genotyping
CFTR genotyping was performed using the INNO-LiPA
CF kit (Innogenetics, Ghent, Belgium). When INNO-LiPA
CF kit was not able to detect mutations the whole CFTR gene
was screened by DHPLC (Transgenomic, Omaha, NE, USA)
and direct sequencing. CFTR genotype and CF phenotype
severity were assessed using the data published in scientific
literature [9].MBL2 exon I genotyping was performed using
the Melting Temperature Assay (MTA) [10].
2.3. Statistics
MBL2 genotype and allele frequencies were calculated
by direct gene counting, Chi square test and 22
contingency tables were used for the comparison of all
categorical variants, while ANOVA tests were performed to
calculate differences within average values. All statistical
analyses were performed using the SPSS Software v. 7.0
(SPSS Inc., Chicago, IL).Table 4
CFTR and MBL2 genotypes
CFTR genotypes MBL2 genotypes
AA A0 00
Severe/Severe CFTR genotype
deltaF508/deltaF508 (20) 10 8 2
deltaF508/N1303K (1) 0 1 03. Results
Clinical features of patients admitted to the CF Centre are
shown in Table 1. The group we analysed consists of 25
females (present average age 16.95) and 22 males (present
average age 19.90). There are no differences between malesTable 2
MBL2 allele and genotype frequencies in CF patients and healthy controls
MBL2 CF patients (47) Healthy controls (130)
Genotype
A/A 24/47 (51.1%) 78 /130 (60%)
A/0 21 /47 (44.7%) 45 /130 (35%)
0 /0 2 /47 (4.2%) 7 /130 (5%)
Allele
A 69/94 (73.4%) 201/260 (77.3%)
0 25 /94 (26.6%) 59 /260 (22.7%)and females in median age of the CF diagnosis, number of
individuals with PA colonization and median age of the
colonization. Only one patient (male) out of 47 showed
pancreatic sufficiency. Table 2 shows MBL2 allele and
genotype frequencies in the 47 CF patients and in 130 pan-
ethnic healthy controls. As expected, allele and genotype
frequencies agreed with the Hardy–Weinberg equilibrium.
Clinical characteristics of CF patients normal MBL pro-
ducers (A /A) and CF patients low MBL producers (A /0
and 0 /0) are shown in Table 3. CFTR and MBL2 genotypes
are reported in Table 4.
MBL2 genotype affects both the onset of PA colonisation
as well as patients’ FEV1 values. In fact, the median age of
PA colonisation was significantly lower in MBL2 A/0 anddeltaF508/621+1GYT (3) 2 1 0
1717-1GYA/1717-1GYA (1) 1 0 0
deltaF508/1677delTA (1) 1 0 0
G542X/G542X (1) 0 1 0
deltaF508/1717-1GYA (1) 0 1 0
Total 28 14 12 2
Mild; unknown/unknown CFTR genotype
R1162X/2789+5GYA (6) 3 3 0
2183 AAYG/4016insT (4) 2 2 0
R1162X/R1162X (3) 1 2 0
DI507/2183 AAYG (4) 2 1 0
S466X/R1070Q; 5T (2) 2 1 0
Total 19 10 9 0
C. Trevisiol et al. / Journal of Cystic Fibrosis 4 (2005) 189–191 1910 /0 CF patients (6.29 years) when compared to A/A
patients (11.24; p =0.037). Moreover, the average FEV1
percentage is significantly lower in low MBL producers
(71.3%) than in normal MBL producers (94%; p=0.04).
The influence of the MBL2 genotype on FEV1 is strictly
related to PA colonisation, CFTR mutations/CF phenotype.
In fact, the mean FEV1 values were significantly different
between low and normal MBL producers only in PA
colonized patients ( p =0.04) and in patients showing a
severe genotype ( p =0.01). The average FEV1 values of CF
patients not colonized by PA and CF patients presenting a
mild or unknown genotype did not vary significantly
between low and normal MBL producers.
Although a 16.7% difference between low and normal
MBL producers was evidenced among mean FEV1 values
in patients with mild/unknown CF genotypes, the statistical
significance was not reached due to high standard
deviations.4. Discussion
The correlation between MBL2 genotype and pulmonary
phenotype severity in CF patients has been broadly
described but it is still controversial. Recently, Davies et
al. [11] found that CF patients with 2 structural MBL2
mutations, but no heterozygotes, had more severe pulmonar
clinical symptoms. These were not related to increased rates
of infection with PA and there was no apparent increased
susceptibility to BC. However, Carlsson et al. [12]-who
investigated serum MBL deficiency, MASP-2 gene mutation
and reduced MBL pathway function in CF subjects-reported
that no correlation to reduced lung function could be
demonstrated except in a small group of patients colonized
with S. aureus (which, like BC but unlike PA, binds MBL)
and whose MBL-deficient genotypes were associated with
decreased lung function.
Our data, even if obtained on a small group of Italian CF
patients, show that low MBL producers are characterised by
an earlier onset of PA colonisation of the lungs. Moreover,
in our population, the MBL2 genotype affects FEV1 values
in patients colonized, but it seems not to have any effect in
non-colonized ones (Table 3).
We can also hypothesize a MBL2 involvement in the
inflammation process of lungs. As already suggested by
Garred et al. [3], a deficient removal of apoptotic and
necrotic bodies in loco by MBL may trigger the inflamma-tion of tissues leading then to a worsening of CF patients’
clinical conditions.
In conclusion, MBL2 behaved as a modifier gene in the
cohort of CF patients admitted to our regional CF centre,
while MBL2 genotyping immediately after a CF diagnosis
could be of interest for the follow-up, expecially in low
MBL producer subjects.Acknowledgement
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